| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | SLAM; CD150; CDw150 |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SLAMF1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及SLAMF1抗体的文献摘要信息(部分为示例性内容，具体文献需根据实际检索结果调整)：
1. **标题**：*"SLAMF1 as a novel therapeutic target in T-cell lymphoma via TCR signaling modulation"*
**作者**：Smith A, et al.
**摘要**：研究报道SLAMF1在T细胞淋巴瘤中高表达，开发了一种人源化单克隆抗体，通过阻断SLAMF1与SAP蛋白相互作用，抑制肿瘤细胞增殖并促进凋亡，在小鼠模型中显著缩小肿瘤体积。
2. **标题**：*"Anti-SLAMF1 antibody enhances NK cell-mediated cytotoxicity in multiple myeloma"*
**作者**：Wang L, et al.
**摘要**：该文献发现多发性骨髓瘤细胞表面SLAMF1过表达，通过抗SLAMF1抗体激活NK细胞的杀伤功能，显著提高肿瘤细胞的清除效率，提出其作为免疫治疗的潜在靶点。
3. **标题**：*"SLAMF1 regulates autoimmune inflammation through Th17 cell modulation: Antibody intervention studies"*
**作者**：Garcia-Ruiz C, et al.
**摘要**：研究证明SLAMF1抗体通过抑制Th17细胞分化减轻实验性自身免疫性脑脊髓炎(EAE)症状，揭示了其在自身免疫疾病中的治疗潜力。
4. **标题**：*"Targeting SLAMF1 in chronic lymphocytic leukemia with a bispecific antibody"*
**作者**：Müller H, et al.
**摘要**：开发了一种双特异性抗体同时靶向SLAMF1和CD3.可有效募集T细胞杀伤慢性淋巴细胞白血病(CLL)细胞，体外实验显示显著抗肿瘤活性。
**注意**：以上为模拟示例，实际文献需通过PubMed/Google Scholar等平台检索确认。建议使用关键词“SLAMF1 antibody”、“anti-SLAMF1 therapy”查找最新研究。
SLAMF1 (Signaling Lymphocyte Activation Molecule Family Member 1), also known as CD150. is a cell surface receptor belonging to the SLAM family of immunoregulatory receptors. Expressed on immune cells, including T cells, B cells, dendritic cells, and macrophages, SLAMF1 functions as a self-ligand that modulates both activating and inhibitory signaling pathways. Structurally, it contains an extracellular immunoglobulin variable (IgV)-like domain, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based switch motifs (ITSMs). These ITSMs recruit adaptor proteins like SAP (SLAM-associated protein) to mediate downstream signaling, influencing immune cell activation, differentiation, and cytokine production.
SLAMF1 plays dual roles in immunity. It enhances T-cell and B-cell interactions during adaptive immune responses but also serves as a receptor for measles virus, facilitating viral entry. In cancer, SLAMF1 is implicated in tumor microenvironment regulation, with studies linking its expression to lymphoma progression and immune evasion. Therapeutic antibodies targeting SLAMF1 are being explored to modulate immune responses in malignancies and autoimmune diseases. For instance, blocking SLAMF1 may suppress pathogenic T-cell activity in autoimmunity, while agonistic antibodies could enhance anti-tumor immunity.
Research also highlights SLAMF1's role in immune checkpoint regulation, potentially synergizing with PD-1/CTLA-4 inhibitors. Its aberrant expression in diseases like lupus and chronic lymphocytic leukemia underscores its clinical relevance. However, the functional complexity of SLAMF1 signaling—dependent on SAP and contextual immune cues—requires careful therapeutic targeting to balance efficacy and safety.
×
